Anti-CD20-based therapy of B cell lymphoma: state of the art
- 1 October 2002
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 16 (10), 2004-2015
- https://doi.org/10.1038/sj.leu.2402639
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 63 references indexed in Scilit:
- Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphomaBone Marrow Transplantation, 2002
- In vivo purging and relapse prevention following ASCTBone Marrow Transplantation, 2002
- Rituximab: enhancing stem cell transplantation in mantle cell lymphomaBone Marrow Transplantation, 2002
- Antibodies Stage a Comeback in Cancer TreatmentScience, 1998
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.The Journal of cell biology, 1993
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975